Sign in
Taking people in United StatesPhase 3

Tests semaglutide in girls and women with polycystic ovary syndrome and obesity

Tests semaglutide in girls and women with obesity and polycystic ovary syndrome.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Registry title
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Status
Recruiting
Phase
Phase 3
People taking part
80 people, planned
Started
3 Nov 2023
Expected to end
30 Jun 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Semaglutide Injectable Product (Wegovy and/or Ozempic)
Record updated
31 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for girls and women with obesity and polycystic ovary syndrome (PCOS) and irregular periods. They will get semaglutide for 10 months.

Age
12 to 35 years
Sex
Female only
Disease stage
PCOS with very infrequent periods (oligomenorrhea) and high male-type hormone levels or signs. For under 18, BMI percentile of 95 or higher. For 18 to 35, BMI of 30 kg/m2 or higher, or 27 kg/m2 or higher with a weight-related condition such as high blood pressure.
Earlier treatment
Taking metformin is allowed. If in the metformin group, stable on 1500 mg or more a day for at least 3 months. Hormonal contraception cannot be used during the study. Weight loss medicines in the last 6 months are not allowed.
Biomarker or test result
High male-type hormone (testosterone) levels in the blood or clinical signs of it.

Main reasons for not taking part

  • Personal or family history of medullary thyroid cancer or MEN2
  • Diabetes (hemoglobin A1C of 6.5% (48 mmol/mol) or higher)
  • Currently pregnant or breastfeeding, or wanting pregnancy in the next 12 to 18 months
  • History of pancreatitis, gallstones, severe stomach or bowel disease, or bariatric surgery
  • Kidney disease, or liver disease other than NAFLD

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Female
  • Ages 12-35 years
  • Sedentary- less than 2 hours of moderate (jogging, swimming etc.) exercise a week
  • Oligomenorrhea, on or off metformin, as defined per age category in the most recent 2018 PCOS international guidelines
  • Initial BMI based on age and weight:; If <18 years, initial BMI percentile ≥95; If 18-35 years, initial BMI ≥30 kg/m2 OR initial BMI ≥27 kg/m2 with at least one weight-related comorbid condition, e.g., hypertension or dyslipidemia; Must be weight stable within ±5kg in the 3 months prior to enrollment
  • Diagnosed with PCOS per the most stringent NIH criteria with adaptation for adolescents (oligomenorrhea >24 months post-menarche or primary amenorrhea after age 15 years and clinical/ biochemical hypertestosteronemia
  • Participants cannot be on hormonal contraception, so participants should remain abstinent or use reliable non-hormonal contraception (e.g., copper IUD) for the entire study period. For participants who receive semaglutide, they should avoid pregnancy for at least 2 months after stopping medication to avoid fetal exposure to the medication
  • For participants in the metformin + semaglutide group, participants must have been stable on ≥ 1500 mg of metformin a day for at least 3 months by time of screening

Who cannot take part

  • Use of medications known to affect insulin sensitivity: metformin (cannot have been used in the 3 months prior to screening for the untreated arm of the study), chronic oral steroids, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications, estrogen-containing hormonal contraception (cannot have been used in the 6 months prior to screening), progesterone-containing hormonal contraception (cannot have been used in the 3 months prior to screening). Dermal patch or vaginal ring contraception methods. Weight loss medications or stimulants. Use of other products containing other GLP-1 agonists
  • Weight loss medications in the last 6 months
  • Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Family history of medullary thyroid cancer or thyroid nodule palpated by endocrinologist at screening. - Per approved drug label
  • Severe illness requiring hospitalization within 60 days
  • Diagnosed major psychiatric or developmental disorder limiting informed consent
  • Active symptoms or undergoing treatment for anorexia nervosa or binging/purging disorder 19) Desiring pregnancy in the next 12-18 months. 20) Bariatric surgery 21) Use of THC (smoking or edible) more than 3 days a week 22) Alcohol use-drinking more than 2 drinks, more than 3 days a week 23) Any potential participants who cannot/will not commit to abstinence, use of a copper intrauterine device (IUD), or use of double barrier forms of contraception
  • Diabetes, defined as Hemoglobin A1C ≥6.5%
  • Anemia, defined as Hemoglobin < 12 mg/dL
  • Known liver disease other than NAFLD, or AST or ALT >125 IU/L. 11) Personal history of pancreatitis 12) Known renal disease of any severity or an eGFR at screening of <45ml/min/1.73m2 13) History of severe GI disease (e.g., gastroparesis) 14) History of gallstones 15) Untreated thyroid disease 16) History of hypersensitivity to semaglutide 17) Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreated thyroid disease, tumor, primary ovarian failure, prolactinoma)
  • Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 35 years old?

Where in United States

  • University of Colorado Anschutz/Children's Hospital Colorado AuroraAurora, United StatesContact: Yesenia Garcia ReyesTaking people

About the trial

What the trial wants to find out

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

The 2 groups in the trial

  • Untreated PCOSTreatment being tested

    Participants with PCOS who are not on metformin or hormonal therapy, will receive 10-months of semaglutide intervention. Participants will get either semaglutide as either: Wegovy: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and 1.7mg for the remainder of the study. or Ozempic: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and Wegovy for 1.7mg for the remainder of the study.

    Treatment: Semaglutide Injectable Product (Wegovy and/or Ozempic)

  • PCOS on MetforminTreatment being tested

    Participants with PCOS who are currently on metformin and still not having regular menses, will receive 10-months of semaglutide intervention. Participants in this arm will continue to take their metformin throughout the trial. Participants will get either semaglutide as either: Wegovy: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and 1.7mg for the remainder of the study. or Ozempic: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg 4-weeks, and Wegovy for 1.7mg for the remainder of the study.

    Treatment: Semaglutide Injectable Product (Wegovy and/or Ozempic)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Plain-language title
Tests semaglutide in girls and women with polycystic ovary syndrome and obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05819853, who can take part
Record updated
31 August 2026